QQQ   281.80 (-2.03%)
AAPL   142.57 (-2.77%)
MSFT   245.04 (-2.06%)
META   114.16 (-6.75%)
GOOGL   96.84 (-2.65%)
AMZN   88.28 (-3.00%)
TSLA   179.54 (-1.59%)
NVDA   158.90 (-4.33%)
NIO   13.17 (+2.89%)
BABA   91.03 (+0.56%)
AMD   69.83 (-5.15%)
T   19.11 (+1.92%)
MU   53.45 (-1.09%)
CGC   3.60 (-16.67%)
F   13.26 (-0.90%)
GE   85.03 (+0.44%)
DIS   92.17 (-3.92%)
AMC   6.73 (-9.66%)
PYPL   71.94 (-2.28%)
PFE   49.68 (-2.07%)
NFLX   304.48 (-2.59%)
QQQ   281.80 (-2.03%)
AAPL   142.57 (-2.77%)
MSFT   245.04 (-2.06%)
META   114.16 (-6.75%)
GOOGL   96.84 (-2.65%)
AMZN   88.28 (-3.00%)
TSLA   179.54 (-1.59%)
NVDA   158.90 (-4.33%)
NIO   13.17 (+2.89%)
BABA   91.03 (+0.56%)
AMD   69.83 (-5.15%)
T   19.11 (+1.92%)
MU   53.45 (-1.09%)
CGC   3.60 (-16.67%)
F   13.26 (-0.90%)
GE   85.03 (+0.44%)
DIS   92.17 (-3.92%)
AMC   6.73 (-9.66%)
PYPL   71.94 (-2.28%)
PFE   49.68 (-2.07%)
NFLX   304.48 (-2.59%)
QQQ   281.80 (-2.03%)
AAPL   142.57 (-2.77%)
MSFT   245.04 (-2.06%)
META   114.16 (-6.75%)
GOOGL   96.84 (-2.65%)
AMZN   88.28 (-3.00%)
TSLA   179.54 (-1.59%)
NVDA   158.90 (-4.33%)
NIO   13.17 (+2.89%)
BABA   91.03 (+0.56%)
AMD   69.83 (-5.15%)
T   19.11 (+1.92%)
MU   53.45 (-1.09%)
CGC   3.60 (-16.67%)
F   13.26 (-0.90%)
GE   85.03 (+0.44%)
DIS   92.17 (-3.92%)
AMC   6.73 (-9.66%)
PYPL   71.94 (-2.28%)
PFE   49.68 (-2.07%)
NFLX   304.48 (-2.59%)
QQQ   281.80 (-2.03%)
AAPL   142.57 (-2.77%)
MSFT   245.04 (-2.06%)
META   114.16 (-6.75%)
GOOGL   96.84 (-2.65%)
AMZN   88.28 (-3.00%)
TSLA   179.54 (-1.59%)
NVDA   158.90 (-4.33%)
NIO   13.17 (+2.89%)
BABA   91.03 (+0.56%)
AMD   69.83 (-5.15%)
T   19.11 (+1.92%)
MU   53.45 (-1.09%)
CGC   3.60 (-16.67%)
F   13.26 (-0.90%)
GE   85.03 (+0.44%)
DIS   92.17 (-3.92%)
AMC   6.73 (-9.66%)
PYPL   71.94 (-2.28%)
PFE   49.68 (-2.07%)
NFLX   304.48 (-2.59%)
NYSEAMERICAN:IBIO

iBio - IBIO Stock Forecast, Price & News

$1.59
-0.09 (-5.36%)
(As of 12/6/2022 02:57 PM ET)
Add
Compare
Today's Range
$1.59
$1.71
50-Day Range
N/A
52-Week Range
$1.46
$18.75
Volume
458 shs
Average Volume
76,472 shs
Market Capitalization
$14.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50

iBio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
2,258.5% Upside
$37.50 Price Target
Short Interest
Bearish
10.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of iBio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.53 out of 5 stars

IBIO stock logo

About iBio (NYSEAMERICAN:IBIO) Stock

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202 , which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Stock News Headlines

iBio Announces CEO Departure
iBio Accelerates Transformation to AI-Powered Biotech
iBio, Inc. (IBIO)
3 Healthcare Stocks to Sell Before They Die - InvestorPlace
Ibio earnings, Revenue miss in Q1 - Investing.com India
iBio reports FY results (NYSE:IBIO) - Seeking Alpha
iBio Q4 2022 Earnings Preview - Seeking Alpha
Here's what Wall Street expects from iBio's earnings report
See More Headlines
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Company Calendar

Last Earnings
11/15/2021
Today
12/06/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:IBIO
Previous Symbol
NASDAQ:IBIO
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.50
High Stock Price Forecast
$37.50
Low Stock Price Forecast
$37.50
Forecasted Upside/Downside
+2,258.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-50,300,000.00
Net Margins
-2,004.10%
Pretax Margin
-2,290.21%

Debt

Sales & Book Value

Annual Sales
$2.38 million
Book Value
$7.27 per share

Miscellaneous

Free Float
8,793,000
Market Cap
$14.33 million
Optionable
Not Optionable
Beta
-3.79

Key Executives

  • Mr. Thomas F. Isett III (Age 57)
    CEO, Pres & Exec. Director
    Comp: $1.06M
  • Mr. Robert Matthew Lutz (Age 53)
    Chief Financial & Bus. Officer
    Comp: $616.57k
  • Dr. Martin B. Brenner D.V.M. (Age 51)
    Ph.D., Chief Scientific Officer
    Comp: $578.3k
  • Mr. Robert B. Kay (Age 82)
    Interim Sec. & Interim Treasurer
    Comp: $92.69k
  • Mike Jenkins
    VP of Operations
  • Stephen Kilmer
    Investor Relations Officer
  • Mr. Marc Banjak J.D.
    Gen. Counsel
  • Dr. Nick DeLong Ph.D.
    VP of Corp. Devel.
  • Ms. Lisa Middlebrook
    Chief HR Officer
  • Mr. Randy Joe Maddux (Age 61)
    Strategic Advisor













IBIO Stock - Frequently Asked Questions

Should I buy or sell iBio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IBIO shares.
View IBIO analyst ratings
or view top-rated stocks.

What is iBio's stock price forecast for 2023?

2 Wall Street analysts have issued 12 month price targets for iBio's stock. Their IBIO share price forecasts range from $37.50 to $37.50. On average, they anticipate the company's stock price to reach $37.50 in the next twelve months. This suggests a possible upside of 2,258.5% from the stock's current price.
View analysts price targets for IBIO
or view top-rated stocks among Wall Street analysts.

How have IBIO shares performed in 2022?

iBio's stock was trading at $11.9650 at the beginning of the year. Since then, IBIO shares have decreased by 86.7% and is now trading at $1.59.
View the best growth stocks for 2022 here
.

Are investors shorting iBio?

iBio saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 960,800 shares, an increase of 15.7% from the October 31st total of 830,100 shares. Based on an average daily volume of 136,400 shares, the short-interest ratio is currently 7.0 days. Approximately 11.0% of the company's shares are short sold.
View iBio's Short Interest
.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) announced its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($1.00) EPS for the quarter, topping analysts' consensus estimates of ($1.25) by $0.25. The biotechnology company earned $0.21 million during the quarter. iBio had a negative trailing twelve-month return on equity of 74.73% and a negative net margin of 2,004.10%.

When did iBio's stock split?

iBio's stock reverse split on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Who are iBio's major shareholders?

iBio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (131.95%), BlackRock Inc. (75.47%), Renaissance Technologies LLC (14.30%), Ergoteles LLC (9.28%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Eastern Capital Ltd, James P Mullaney, Robert L Erwin and Robert Matthew Lutz.
View institutional ownership trends
.

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $1.59.

How much money does iBio make?

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $14.33 million and generates $2.38 million in revenue each year. The biotechnology company earns $-50,300,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (302) 355-0650, via email at ir@ibioinc.com, or via fax at 302-356-1173.

This page (NYSEAMERICAN:IBIO) was last updated on 12/6/2022 by MarketBeat.com Staff